Active	Status	Sponsor type	Region	Phase	Filter
33 Active 21 Inactive 54 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

10 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Deeks, Steven G
PREVAIL-LC, NCT06161688: Ensitrelvir for Viral Persistence and Inflammation in People Experiencing Long COVID	Active, not recruiting	2	40	US	Ensitrelvir, ensitrelvir fumaric acid, Placebo	Timothy Henrich, Shionogi Inc.	Long COVID, Post Acute Sequelae of COVID-19, Post-Acute COVID-19	06/25	12/25
NCT03684655: Imaging Immune Activation in HIV by PET-MR	Recruiting	2	30	US	[18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine), VisAcT	CellSight Technologies, Inc., National Institute of Allergy and Infectious Diseases (NIAID), University of California, San Francisco	HIV Infections	10/25	11/25
NCT03174977: Pharmacokinetics Distribution of Raltegravir by PET/MR	Recruiting	1	10	US	18F-Raltegravir	University of California, San Francisco, Merck Sharp & Dohme LLC	HIV-1-infection	11/24	01/25
Hsue, Priscilla
PREVAIL-LC, NCT06161688: Ensitrelvir for Viral Persistence and Inflammation in People Experiencing Long COVID	Active, not recruiting	2	40	US	Ensitrelvir, ensitrelvir fumaric acid, Placebo	Timothy Henrich, Shionogi Inc.	Long COVID, Post Acute Sequelae of COVID-19, Post-Acute COVID-19	06/25	12/25
Henrich, Timothy
PREVAIL-LC, NCT06161688: Ensitrelvir for Viral Persistence and Inflammation in People Experiencing Long COVID	Active, not recruiting	2	40	US	Ensitrelvir, ensitrelvir fumaric acid, Placebo	Timothy Henrich, Shionogi Inc.	Long COVID, Post Acute Sequelae of COVID-19, Post-Acute COVID-19	06/25	12/25
NCT03684655: Imaging Immune Activation in HIV by PET-MR	Recruiting	2	30	US	[18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine), VisAcT	CellSight Technologies, Inc., National Institute of Allergy and Infectious Diseases (NIAID), University of California, San Francisco	HIV Infections	10/25	11/25
NCT04815096: Imaging Immune Activation in COVID-19	Recruiting	2	80	US	[18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine), VisAcT	CellSight Technologies, Inc., University of California, San Francisco	Covid19, SARS-CoV Infection	10/25	10/25
NCT03174977: Pharmacokinetics Distribution of Raltegravir by PET/MR	Recruiting	1	10	US	18F-Raltegravir	University of California, San Francisco, Merck Sharp & Dohme LLC	HIV-1-infection	11/24	01/25
NCT05244473: A Safety Study of Brentuximab Vedotin in Participants With HIV	Withdrawn	1	48	US	brentuximab vedotin, ADCETRIS, Placebo, ART	Seagen Inc.	Human Immunodeficiency Virus	05/24	05/24
Peluso, Michael J
PREVAIL-LC, NCT06161688: Ensitrelvir for Viral Persistence and Inflammation in People Experiencing Long COVID	Active, not recruiting	2	40	US	Ensitrelvir, ensitrelvir fumaric acid, Placebo	Timothy Henrich, Shionogi Inc.	Long COVID, Post Acute Sequelae of COVID-19, Post-Acute COVID-19	06/25	12/25